The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.35% from 2023 to 2030. The growth can be attributed to the rising usage of gabapentin for neuropathic pain and the increasing incidence of associated diseases such as epilepsy globally. The other key growth driver is the rising geriatric population which is more to epilepsy and conditions such as neuropathic pain.
The growing demand for generics in the market is creating an opportunity for major generic players, however, the opportunity is more lucrative in the lower and middle-income nations due to the high preference for these drugs. Moreover, developed regions such as North America and Europe are further making policy changes to reduce the burden on the healthcare system by promoting the use of generics such as gabapentin.
Gabapentin is majorly available in three dosage forms, namely, tablet, capsule, and oral solution. The capsules segment held the largest market share in 2022, owing to the presence of major branded products and the ease of availability. Due to the discovery that gabapentin carries a risk of addiction and overdose, some nations have scrutinized its usage and placed limitations on it. Long-term growth for gabapentin may be impacted by such discoveries, which may push drugmakers to concentrate on creating safer and more potent painkillers.
North America is expected to dominate the market over the forecast period, due to a developed healthcare system that facilitates the adoption of drugs such as gabapentin. However, other regions such as Asia Pacific are growing at a faster rate attributable to the presence of key generic players and the rising awareness about the adoption of pharmaceutical treatments for diseases over traditional therapies, majorly used in Asian countries.
Some of the key competitors in the gabapentin industry include Sun Pharmaceutical Industries Ltd.; Ascend Laboratories, LLC; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, Inc.; and Pfizer Inc. The downfall of branded products is leading to the shift of competition toward generic products. This is increasing the competitive rivalry due to increased marketplace saturation of players and products.
The growing demand for generics in the market is creating an opportunity for major generic players, however, the opportunity is more lucrative in the lower and middle-income nations due to the high preference for these drugs. Moreover, developed regions such as North America and Europe are further making policy changes to reduce the burden on the healthcare system by promoting the use of generics such as gabapentin.
Gabapentin is majorly available in three dosage forms, namely, tablet, capsule, and oral solution. The capsules segment held the largest market share in 2022, owing to the presence of major branded products and the ease of availability. Due to the discovery that gabapentin carries a risk of addiction and overdose, some nations have scrutinized its usage and placed limitations on it. Long-term growth for gabapentin may be impacted by such discoveries, which may push drugmakers to concentrate on creating safer and more potent painkillers.
North America is expected to dominate the market over the forecast period, due to a developed healthcare system that facilitates the adoption of drugs such as gabapentin. However, other regions such as Asia Pacific are growing at a faster rate attributable to the presence of key generic players and the rising awareness about the adoption of pharmaceutical treatments for diseases over traditional therapies, majorly used in Asian countries.
Some of the key competitors in the gabapentin industry include Sun Pharmaceutical Industries Ltd.; Ascend Laboratories, LLC; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, Inc.; and Pfizer Inc. The downfall of branded products is leading to the shift of competition toward generic products. This is increasing the competitive rivalry due to increased marketplace saturation of players and products.
Gabapentin Market Report Highlights
- The capsule segment dominated the market in 2022, due to the ease of access to the capsule form of the drug
- The generic segment is expected to showcase the fastest CAGR over the forecast period, owing to increased preference for generic drugs over branded products globally, majorly due to cost-effectiveness
- The hospitals segment dominated the market in 2022, due to the ease of availability of treatment in hospital settings
- North America held the largest market share in 2022 which can be attributed to the increasing prevalence of associated diseases such as epilepsy and neuropathic pain among the population along with growing investments to provide effective treatment
- A few key market players include Zydus Pharmaceuticals, Inc; Glenmark Pharmaceuticals Limited; Sun Pharmaceutical Industries Ltd.; Ascend Laboratories, LLC; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Aurobindo Pharma.; Amneal Pharmaceuticals LLC.; Cipla USA, Inc.; BP Pharmaceuticals Laboratories Company; Assertio Holdings, Inc.; Arbor Pharmaceuticals, Inc.; and Pfizer Inc.
Table of Contents
Chapter 1 Gabapentin Market: Methodology And Scope1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using a bottom-up approach
1.6.1.3 Approach 2: Country-wise market estimation using a top-down approach
1.7 Global Market: CAGR Calculation
1.8 List of Secondary Sources
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.10 List of Abbreviations
Chapter 2 Gabapentin Market: Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Gabapentin Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Increased prevalence of target diseases
3.2.1.2 Rising awareness campaigns and prevention programs
3.2.1.3 Increasing entry of generics in the market
3.2.2 Market Restraint Analysis
3.2.2.1 Increased Number Of The Addicted Population
3.2.2.2 Increased Misuse Of Gabapentin
3.3. Market Opportunity Analysis
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis - Porter’s
Chapter 4 Gabapentin Market: Dosage Form Business Analysis
4.1 Definition and Scope
4.2 Dosage Form Market Share Analysis, 2022 & 2030
4.3 Global Gabapentin Market, By Dosage Form, 2018 To 2030
4.4 Gabapentin Market: Dosage Form Movement Analysis
4.5 Tablet
4.5.1 Tablet Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.6 Capsule
4.6.1 Capsule Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.7 Oral Solution
4.7.1 Oral Solution Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 5 Gabapentin Market: Type Business Analysis
5.1 Definition and Scope
5.2 Type Market Share Analysis, 2022 & 2030
5.3 Global Gabapentin Market, By Type, 2018 To 2030
5.4 Gabapentin Market: Type Movement Analysis
5.5 Generic
5.5.1 Generic Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.6 Branded
5.6.1 Branded Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Gabapentin Market: Application Business Analysis
6.1 Definition and Scope
6.2 Application Market Share Analysis, 2022 & 2030
6.3 Global Gabapentin Market, By Application, 2018 To 2030
6.4 Gabapentin Market: Application Movement Analysis
6.5 Epilepsy
6.5.1 Epilepsy Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.6 Neuropathic Pain
6.6.1 Neuropathic Pain Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.7 Restless Legs Syndrome
6.7.1 Restless Legs Syndrome Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.8 Others
6.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Gabapentin Market: Distribution Channel Business Analysis
7.1 Definition and Scope
7.2 Distribution Channel Market Share Analysis, 2022 & 2030
7.3 Global Gabapentin Market, By Distribution Channel, 2018 To 2030
7.4 Gabapentin Market: Distribution Channel Movement Analysis
7.5 Hospital Pharmacy
7.5.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6 Retail Pharmacy
7.6.1 Retail Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.7 Online Pharmacy
7.7.1 Online Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Gabapentin Market: Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2022 & 2030
7.3 North America
7.3.1 North America Gabapentin Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.2 U.S.
7.3.2.1 U.S. Gabapentin Market, 2018 - 2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Regulatory Framework
7.3.2.4 Competitive Scenario
7.3.3 Canada
7.3.3.1 Canada Gabapentin Market, 2018 - 2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Regulatory Framework
7.3.3.4 Competitive Scenario
7.4 Europe
7.4.1 Europe Gabapentin Market, 2018 - 2030 (USD Million)
7.4.2 U.K.
7.4.2.1 Uk Gabapentin Market, 2018 - 2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Regulatory Framework
7.4.2.4 Competitive Scenario
7.4.3 Germany
7.4.3.1 Germany Gabapentin Market, 2018 - 2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Regulatory Framework
7.4.3.4 Competitive Scenario
7.4.4 Spain
7.4.4.1 Spain Gabapentin Market, 2018 - 2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Regulatory Framework
7.4.4.4 Competitive Scenario
7.4.5 France
7.4.5.1 France Gabapentin Market, 2018 - 2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Regulatory Framework
7.4.5.4 Competitive Scenario
7.4.6 Italy
7.4.6.1 Italy Gabapentin Market, 2018 - 2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Regulatory Framework
7.4.6.4 Competitive Scenario
7.4.7 Norway
7.4.7.1 Norway Gabapentin Market, 2018 - 2030 (USD Million)
7.4.7.3 Regulatory Framework
7.4.7.4 Competitive Scenario
7.4.8 Denmark
7.4.8.1 Denmark Gabapentin Market, 2018 - 2030 (USD Million)
7.4.8.2 Key Country Dynamics
7.4.8.3 Regulatory Framework
7.4.8.4 Competitive Scenario
7.4.9 Sweden
7.4.9.1 Sweden Gabapentin Market, 2018 - 2030 (USD Million)
7.4.9.2 Key Country Dynamics
7.4.9.3 Regulatory Framework
7.4.9.4 Competitive Scenario
7.4.10 Rest Of Europe
7.4.10.1 Rest Of Europe Gabapentin Market, 2018 - 2030 (USD Million)
7.5 Asia Pacific
7.5.1 Asia-Pacific Gabapentin Market, 2018 - 2030 (USD Million)
7.5.2 Japan
7.5.2.1 Japan Gabapentin Market, 2018 - 2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Regulatory Framework
7.5.2.4 Competitive Scenario
7.5.3 China
7.5.3.1 China Gabapentin Market, 2018 - 2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Regulatory Framework
7.5.3.4 Competitive Scenario
7.5.4 India
7.5.4.1 India Gabapentin Market, 2018 - 2030 (USD Million)
7.5.4.2 Key Country Dynamics
7.5.4.3 Regulatory Framework
7.5.4.4 Competitive Scenario
7.5.5 South Korea
7.5.5.1 South Korea Gabapentin Market, 2018 - 2030 (USD Million)
7.5.5.2 Key Country Dynamics
7.5.5.3 Regulatory Framework
7.5.5.4 Competitive Scenario
7.5.6 Thailand
7.5.6.1 Thailand Gabapentin Market, 2018 - 2030 (USD Million)
7.5.6.2 Key Country Dynamics
7.5.6.3 Regulatory Framework
7.5.6.4 Competitive Scenario
7.5.7 Australia
7.5.7.1 Australia Gabapentin Market, 2018 - 2030 (USD Million)
7.5.7.2 Key Country Dynamics
7.5.7.3 Regulatory Framework
7.5.7.4 Competitive Scenario
7.5.8 Rest Of Apac
7.5.8.1 Rest Of Apac Gabapentin Market, 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1 Latin America Gabapentin Market, 2018 - 2030 (USD Million)
7.6.2 Brazil
7.6.2.1 Brazil Gabapentin Market, 2018 - 2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Regulatory Framework
7.6.2.4 Competitive Scenario
7.6.3 Mexico
7.6.3.1 Mexico Gabapentin Market, 2018 - 2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Regulatory Framework
7.6.3.4 Competitive Scenario
7.6.4 Argentina
7.6.4.1 Argentina Gabapentin Market, 2018 - 2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Regulatory Framework
7.6.4.4 Competitive Scenario
7.6.5 Rest Of Latam
7.6.5.1 Rest Of Latam Gabapentin Market, 2018 - 2030 (USD Million)
7.7. MEA
7.7.1 MEA Gabapentin Market, 2018 - 2030 (USD Million)
7.7.2 South Africa
7.7.2.1 South Africa Gabapentin Market, 2018 - 2030 (USD Million)
7.7.2.2 Key Country Dynamics
7.7.2.3 Regulatory Framework
7.7.2.4 Competitive Scenario
7.7.3 Saudi Arabia
7.7.3.1 Saudi Arabia Gabapentin Market, 2018 - 2030 (USD Million)
7.7.3.2 Key Country Dynamics
7.7.3.3 Regulatory Framework
7.7.3.4 Competitive Scenario
7.7.4 UAE
7.7.4.1 UAE Gabapentin Market, 2018 - 2030 (USD Million)
7.7.4.2 Key Country Dynamics
7.7.4.3 Regulatory Framework
7.7.4.4 Competitive Scenario
7.7.5 Kuwait
7.7.5.1 Kuwait Gabapentin Market, 2018 - 2030 (USD Million)
7.7.5.2 Key Country Dynamics
7.7.5.3 Regulatory Framework
7.7.5.4 Competitive Scenario
7.7.6 Rest Of MEA
7.7.6.1 Rest Of MEA Gabapentin Market, 2018 - 2030 (USD Million)
Chapter 8 Gabapentin Market: Company Profiling
8.1 Company Categorization
8.2 Participant’s Overview
8.3 Financial Performance
8.4 Product Benchmarking
8.5 Company Market Positioning
8.6 Company Strategy Mapping
8.6.1 Expansion
8.6.2 Acquisition
8.6.3 Collaborations
8.6.4 Product/Service Launch
8.6.5 Partnerships
8.6.6 Others
8.7 Company Profiles
8.7.1 Zydus Pharmaceuticals, Inc.
8.7.1.1 Company Overview
8.7.1.2 Financial Performance
8.7.1.3 Product Benchmarking
8.7.1.4 Strategic Initiatives
8.7.2 Glenmark Pharmaceuticals Limited
8.7.2.1 Company Overview
8.7.2 2.Financial Performance
8.7.2.3 Product Benchmarking
8.7.2.4 Strategic Initiatives
8.7.3 Sun Pharmaceutical Industries Ltd.
8.7.3.1 Company Overview
8.7.3.2 Financial Performance
8.7.3.3 Product Benchmarking
8.7.3.4 Strategic Initiatives
8.7.4 Ascend Laboratories, Llc
8.7.4.1 Company Overview
8.7.4.2 Financial Performance
8.7.4.3 Product Benchmarking
8.7.4.4 Strategic Initiatives
8.7.5 Apotex Inc
8.7.5.1 Company Overview
8.7.5.2 Financial Performance
8.7.5.3 Product Benchmarking
8.7.5.4 Strategic Initiatives
8.7.6 Aurobindo Pharma
8.7.6.1 Company Overview
8.7.6.2 Financial Performance
8.7.6.3 Product Benchmarking
8.7.6.4 Strategic Initiatives
8.7.7 Amneal Pharmaceuticals Llc.
8.7.7.1 Company Overview
8.7.7.2 Financial Performance
8.7.7.3 Product Benchmarking
8.7.7.4 Strategic Initiatives
8.7.8 Cipla, Inc.
8.7.8.1 Company Overview
8.7.8.2 Financial Performance
8.7.8.3 Product Benchmarking
8.7.8.4 Strategic Initiatives
8.7.9 Bp Pharmaceuticals Laboratories Company
8.7.9.1 Company Overview
8.7.9.2 Financial Performance
8.7.9.3 Product Benchmarking
8.7.9.4 Strategic Initiatives
8.7.10 Assertio Holdings, Inc.
8.7.10.1 Company Overview
8.7.10.2 Financial Performance
8.7.10.3 Product Benchmarking
8.7.10.4 Strategic Initiatives
8.7.11 Arbor Pharmaceuticals, Inc.
8.7.11.1 Company Overview
8.7.11.2 Financial Performance
8.7.11.3 Product Benchmarking
8.7.11.4 Strategic Initiatives
8.7.12 Pfizer Inc.
8.7.12.1 Company Overview
8.7.12.2 Financial Performance
8.7.12.3 Product Benchmarking
8.7.12.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Incidence of Diseases
Table 4 Global Gabapentin Market, By Region, 2018 - 2030 (USD Million)
Table 5 North America Gabapentin Market, By Country, 2018 - 2030 (USD Million)
Table 6 North America Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 7 North America Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 8 North America Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 9 North America Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S. Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 11 U.S. Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 12 U.S. Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 13 U.S. Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Canada Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 15 Canada Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 16 Canada Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 17 Canada Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 18 Europe Gabapentin Market, By Country, 2018 - 2030 (USD Million)
Table 19 Europe Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 20 Europe Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 21 Europe Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 22 Europe Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 23 Germany Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 24 Germany Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 25 Germany Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 26 Germany Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 27 U.K. Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 28 U.K. Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 29 U.K. Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 30 U.K. Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 31 France Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 32 France Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 33 France Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 34 France Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 35 Italy Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 36 Italy Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 37 Italy Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 38 Italy Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 39 Spain Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 40 Spain Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 41 Spain Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 42 Spain Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Denmark Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 44 Denmark Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 45 Denmark Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 46 Denmark Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Sweden Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 48 Sweden Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 49 Sweden Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 50 Sweden Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Norway Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 52 Norway Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 53 Norway Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 54 Norway Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 Asia Pacific Gabapentin Market, By Country, 2018 - 2030 (USD Million)
Table 56 Asia Pacific Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 57 Asia Pacific Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 58 Asia Pacific Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 59 Asia Pacific Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 60 Japan Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 61 Japan Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 62 Japan Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 63 Japan Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 64 China Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 65 China Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 66 China Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 67 China Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 68 India Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 69 India Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 70 India Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 71 India Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 72 South Korea Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 73 South Korea Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 74 South Korea Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 75 South Korea Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 76 Australia Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 77 Australia Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 78 Australia Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 79 Australia Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 80 Thailand Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 81 Thailand Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 82 Thailand Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 83 Thailand Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 84 Latin America Gabapentin Market, By Country, 2018 - 2030 (USD Million)
Table 85 Latin America Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 86 Latin America Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 87 Latin America Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 88 Latin America Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 89 Brazil Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 90 Brazil Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 91 Brazil Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 92 Brazil Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 93 Mexico Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 94 Mexico Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 95 Argentina Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 96 Argentina Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 97 Argentina Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 98 Argentina Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 99 Middle East & Africa Gabapentin Market, By Country, 2018 - 2030 (USD Million)
Table 100 Middle East & Africa Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 101 Middle East & Africa Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 102 Middle East & Africa Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 103 Middle East & Africa Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 104 Saudi Arabia Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 105 Saudi Arabia Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 106 Saudi Arabia Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 108 South Africa Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 109 South Africa Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 110 South Africa Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 111 South Africa Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 112 UAE Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 113 UAE Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 114 UAE Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 115 UAE Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 116 Kuwait Gabapentin Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 117 Kuwait Gabapentin Market, By Type, 2018 - 2030 (USD Million)
Table 118 Kuwait Gabapentin Market, By Application, 2018 - 2030 (USD Million)
Table 119 Kuwait Gabapentin Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Gabapentin Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Market Penetration & Growth Prospect Mapping
Fig. 15 Gabapentin market: Dosage Form outlook and key takeaways
Fig. 16 Gabapentin market: Dosage Form movement analysis & market share 2022 & 2030
Fig. 17 Tablet market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Capsule market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Oral Solution market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Gabapentin market: Type outlook and key takeaways
Fig. 21 Gabapentin market: Type movement analysis & market share 2022 & 2030
Fig. 22 Generic market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Branded market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Gabapentin market: Application outlook and key takeaways
Fig. 25 Gabapentin market: Application movement analysis & market share 2022 & 2030
Fig. 26 Epilepsy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Neuropathic pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Restless Legs Syndrome market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Gabapentin market: Distribution Channel outlook and key takeaways
Fig. 31 Gabapentin market: Distribution Channel movement analysis & market share 2022 & 2030
Fig. 32 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Regional Marketplace: Key Takeaways
Fig. 36 Regional Outlook, 2022 & 2030
Fig. 37 Regional Market Dashboard
Fig. 38 Regional Market Place: Key Takeaways
Fig. 39 North America
Fig. 40 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 41 U.S.
Fig. 42 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 43 Canada
Fig. 44 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 45 Europe
Fig. 46 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 47 U.K.
Fig. 48 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 49 Germany
Fig. 50 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 51 France
Fig. 52 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 53 Italy
Fig. 54 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 55 Spain
Fig. 56 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 57 Denmark
Fig. 58 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 59 Sweden
Fig. 60 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 61 Norway
Fig. 62 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 63 Asia Pacific
Fig. 64 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 65 Japan
Fig. 66 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 67 China
Fig. 68 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 69 India
Fig. 70 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 71 Australia
Fig. 72 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 73 Thailand
Fig. 74 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 75 South Korea
Fig. 76 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 77 Latin America
Fig. 78 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 79 Brazil
Fig. 80 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 81 Mexico
Fig. 82 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 83 Argentina
Fig. 84 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 85 MEA
Fig. 86 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 87 South Africa
Fig. 88 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 89 Saudi Arabia
Fig. 90 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 91 UAE
Fig. 92 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 93 Kuwait
Fig. 94 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 95 Strategy Mapping
Companies Mentioned
- Zydus Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Limited
- Sun Pharmaceutical Industries Ltd.
- Ascend Laboratories, Llc
- Apotex Inc
- Aurobindo Pharma
- Amneal Pharmaceuticals Llc.
- Cipla, Inc.
- Bp Pharmaceuticals Laboratories Company
- Assertio Holdings, Inc.
- Arbor Pharmaceuticals, Inc.
- Pfizer Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | March 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 2022.84 Million |
| Forecasted Market Value ( USD | $ 3070 Million |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
